StockNews.AI

Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery

StockNews.AI • 5 hours

BIOTMDVLAVNS
High Materiality8/10

Information

KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd....

Original source

AI Summary

Kestra collaborates with Biobeat to enhance cardiac care diagnostics. Agreement includes $5 million investment in Biobeat’s Series B financing. Integration of Biobeat’s ABPM technology will support ASSURE WCD users. ACE-PAS study highlights 72% hypertension prevalence in evaluated patients. Collaboration aims to expand clinical insights for managing complex cardiac cases.

Sentiment Rationale

The collaboration enhances KMTS's product offering and market relevance, similar to past successful partnerships in healthcare technology that increased stock values.

Trading Thesis

The integration of new technology and improved clinical insights is likely to build steady revenue streams over time.

Market-Moving

  • Kestra collaborates with Biobeat to enhance cardiac care diagnostics.
  • Agreement includes $5 million investment in Biobeat’s Series B financing.
  • Integration of Biobeat’s ABPM technology will support ASSURE WCD users.

Key Facts

  • Kestra collaborates with Biobeat to enhance cardiac care diagnostics.
  • Agreement includes $5 million investment in Biobeat’s Series B financing.
  • Integration of Biobeat’s ABPM technology will support ASSURE WCD users.
  • ACE-PAS study highlights 72% hypertension prevalence in evaluated patients.
  • Collaboration aims to expand clinical insights for managing complex cardiac cases.

Companies Mentioned

  • BIOT (BIOT)
  • MDVL (MDVL)
  • AVNS (AVNS)

Corporate Developments

The strategic collaboration and investment signals growth potential, enhancing KMTS's market position amidst increasing demand for healthcare innovations.

Kestra Medical Technologies Partners with Biobeat to Enhance Wearable Defibrillator Patient Insights

KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a pioneer in wearable medical devices and digital healthcare solutions, has announced a strategic partnership with Biobeat Technologies, Ltd. This collaboration aims to enhance diagnostic capabilities for patients using the ASSURE® Wearable Cardioverter Defibrillator (WCD). The agreement includes an exclusive license, co-development efforts, and a substantial $5 million equity investment in Biobeat’s recent Series B financing round.

Innovative Blood Pressure Monitoring Technology

Biobeat is renowned for its groundbreaking, FDA-cleared cuffless, patch-worn ambulatory blood pressure monitoring (ABPM) device. This technology leverages photoplethysmography-based sensing, providing continuous and non-invasive blood pressure readings over a 24-hour period. Such advancements are critical for diagnosing and managing hypertension, especially during outpatient cardiac recovery.

Kestra Medical plans to integrate Biobeat’s technology into its product offerings, thereby making ABPM data accessible for patients using the ASSURE WCD. This integration aligns with Kestra’s commitment to improving patient outcomes in cardiovascular healthcare.

Clinical Relevance Highlighted by Recent Research

Kestra recently published the largest prospective real-world study of wearable defibrillators to date, revealing significant insights. The findings from the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS) indicated that 72% of the participants were hypertensive. This underscores the complexities involved in managing blood pressure during cardiac recovery and the necessity for effective monitoring during guideline-directed medical therapy (GDMT) optimization.

“Health care providers have consistently told us that better visibility to blood pressures during cardiac recovery would meaningfully support clinical decision-making,” stated Brian Webster, President and CEO of Kestra. “This collaboration allows us to expand the clinical insights available during recovery while reinforcing ASSURE as a flexible platform designed to support at-home patient care.”

Vision for Advanced Cardiac Recovery Monitoring

Arik Ben Ishay, CEO of Biobeat, expressed enthusiasm for the collaboration, stating, “Kestra has built a scalable platform focused on protecting and supporting patients during cardiac recovery. We are excited to collaborate as they explore how our FDA-cleared 24-hour blood pressure monitoring for hypertension diagnosis may complement their Cardiac Recovery System® platform, thereby expanding the clinical insights available to care teams managing complex cardiac patients.”

About the Companies

Kestra Medical Technologies, Ltd. is dedicated to transforming patient outcomes in cardiovascular disease through user-friendly monitoring and therapeutic intervention technologies. To learn more, visit www.kestramedical.com.

Biobeat, with operations in Tel Aviv, Israel, and Boca Raton, Florida, aims to revolutionize blood pressure monitoring by extending the use of ABPM and enabling seamless and accurate collection of critical nighttime data. For further information, visit www.bio-beat.com.

Forward-Looking Statements

The information in this announcement is accurate as of January 13, 2026. This press release may contain forward-looking statements that express beliefs, expectations, or intentions that involve risks and uncertainties. Actual results may differ materially due to various factors, including market adoption rates and regulatory challenges. For detailed information, refer to Kestra’s filings with the U.S. Securities and Exchange Commission (SEC) available at https://investors.kestramedical.com/ and https://sec.gov/.

Related News